| Title | Phase 2 Multi-center Study of Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) w/Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs) |
|---|---|
| Disease/Condition | Lung Cancer,Lung Diseases,Carcinoma,Neoplasms |
| Description | |
| Eligibility Criteria | Click here for eligibility requirements |
| Principal Investigator | Balazs Halmos, MD |
| Contact Name | Remy Lambert |
| Contact Email | rlambert@montefiore.org |
| Protocol Number | 2017-8355 |
| Inclusion/Notes | This Information was obtained from ClinicalTrials.gov |
| Status | Active/Enrolling |
| Adult Clinical Trial | Yes |
| Pediatric Clinical Trial | No |
| Sub-Specialty | Medical and Hematologic Oncology - Lung |
| Adult, Pediatric, Both | Adult |